About this blog

CRIT is no longer adding posts or updating the CRITical Thinking blog.

CRITical Thinking is a blog written by staff, directors, and friends of the Collaboration for Research Integrity and Transparency (CRIT), a joint program of Yale Law School, Yale School of Public Health, and Yale School of Medicine. CRIT's mission is to promote health by improving the integrity and transparency of biomedical and clinical research.

This blog is published by and reflects the personal views of the individual authors, in their individual capacities. It does not purport to represent Yale University's institutional views, if any. No representation is made about the accuracy of the information, which solely constitutes the authors’ personal views on issues discussed. The information contained in this blog is provided only as general information and personal opinions, and blog topics may be updated after being initially posted.

 

CRITical Thinking Blog

Why High Quality Evidence Matters: Lessons from HIV Activism and Drug Development

August 21, 2017
By Simon Collins

In June 2017, Yale CRIT hosted an international conference titled “Ensuring Safety, Efficacy, and Access to Medical Products in the Age of Global Deregulation.” The following blogpost is the second installment of a blog series with commentaries from the conference participants.

Read more

CRITical Thinking Blog Series—Ensuring Safety, Efficacy, & Access to Medical Products in the Age of Global Deregulation

August 14, 2017
By Gregg Gonsalves, Jeanie Kim

In June 2017, the Yale Collaboration for Research Integrity and Transparency (CRIT) in partnership with the European Public Health Alliance sponsored an international conference titled “Ensuring Safety, Efficacy, and Access to Medical Products in the Age of Global Deregulation.”

Read more

FDA Regulatory Review: It’s still faster

April 6, 2017
By Audrey D. Zhang, Nicholas S. Downing, Joseph S. Ross

The speed with which the Food and Drug Administration (FDA) reviews new drug, biologic and medical device applications remains a contentious subject of criticism. And with attention focused on the impending reauthorization of the Prescription Drug User Fee Act (PDUFA), it’s worth revisiting the commonly heard rhetoric that FDA regulatory review is too slow.

Read more

Pages